Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 3/20 | 0.37 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.37 |
| ▸ | FDPS | P14324 | 10/20 | 0.34 |
| ▸ | GGPS1 | O95749 | 6/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14743017 | 0.85 | FDPS (0.38) | FDPSALDH1A1 | |
| SCHEMBL14742641 | 0.83 | ESR1 (0.37) | ESR1ESR2FDPSGGPS1ALDH1A1 | |
| SCHEMBL14743432 | 0.83 | ESR1 (0.37) | ESR1ESR2FDPSGGPS1ALDH1A1 | |
| SCHEMBL14743039 | 0.78 | — | — | |
| SCHEMBL2349836 | 0.77 | ESR1 (0.39) | ESR1ESR2FDPSGGPS1ALDH1A1 | |
| SCHEMBL525776 | 0.77 | — | — | |
| SCHEMBL3801327 | 0.77 | — | — | |
| SCHEMBL14844470 | 0.74 | ESR1 (0.38) | ESR1ESR2FDPSGGPS1ALDH1A1 | |
| SCHEMBL4671665 | 0.74 | ESR1 (0.38) | ESR1ESR2FDPSGGPS1ALDH1A1 | |
| SCHEMBL21086309 | 0.74 | ESR1 (0.38) | ESR1ESR2FDPSGGPS1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9751876-B2 | Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension | NOVARTIS AG (CH) | 2017-09-05 | — | — | US | disclosed |
| US-9676907-B2 | Methods and systems of graft polymerization on a functionalized substrate | ASPEN RESEARCH CORPORATION (US) | 2017-06-13 | — | — | US | disclosed |
| US-20160168331-A1 | METHODS AND SYSTEMS OF GRAFT POLYMERIZATION ON A FUNCTIONALIZED SUBSTRATE | JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT | 2016-06-16 | — | — | US | disclosed |
| EP-2751108-B1 | BICYCLIC HETEROCYCLE DERIVATIVES FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION | NOVARTIS AG (CH) | 2016-04-27 | — | — | EP | disclosed |
| US-9267009-B2 | Methods and systems of graft polymerization on a functionalized substrate | ASPEN RESEARCH CORPORATION (US) | 2016-02-23 | — | — | US | disclosed |
| US-9074056-B2 | Methods and systems to prepare functionalized substrate from disulfide bond-containing material | ASPEN RESEARCH CORPORATION (US) | 2015-07-07 | — | — | US | disclosed |
| US-20150025059-A1 | BICYCLIC HETEROCYCLE DERIVATIVES FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION | NOVARTIS AG (CH) | 2015-01-22 | — | — | US | disclosed |
| US-20140343188-A1 | METHODS AND SYSTEMS TO PREPARE FUNCTIONALIZED SUBSTRATE FROM DISULFIDE BOND-CONTAINING MATERIAL | ASPEN RESEARCH CORPORATION (US) | 2014-11-20 | — | — | US | disclosed |
| US-8883819-B2 | Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension | IRM LLC (BM) | 2014-11-11 | — | — | US | disclosed |
| US-20140296366-A1 | METHODS AND SYSTEMS OF GRAFT POLYMERIZATION ON A FUNCTIONALIZED SUBSTRATE | ASPEN RESEARCH CORPORATION (US) | 2014-10-02 | — | — | US | disclosed |
| EP-2751108-A1 | BICYCLIC HETEROCYCLE DERIVATIVES FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION | Novartis AG (CH) | 2014-07-09 | — | — | EP | disclosed |
| US-20130237519-A1 | BICYCLIC HETEROCYCLE DERIVATIVES FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2013-09-12 | — | — | US | disclosed |
| WO-2013030802-A1 | BICYCLIC HETEROCYCLE DERIVATIVES FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION | NOVARTIS AG (CH) | 2013-03-07 | — | — | WO | disclosed |
| WO-2013033614-A1 | METHODS AND SYSTEMS TO PREPARE FUNCTIONALIZED SUBSTRATE FROM DISULFIDE BOND-CONTAINING MATERIAL | ASPEN RESEARCH CORPORATION (US) | 2013-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130237519-A1 | BICYCLIC HETEROCYCLE DERIVATIVES FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION | PDGFA, PDGFRA, PDGFRB | ESR1 3148/4885ESR2 672/4885FDPS 3644/4885 |
| US-20150025059-A1 | BICYCLIC HETEROCYCLE DERIVATIVES FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION | PDGFA, PDGFRA, PDGFRB | ESR1 3148/4885ESR2 672/4885FDPS 3644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.